184 related articles for article (PubMed ID: 38274829)
41. Hederagenin Induces Apoptosis in Cisplatin-Resistant Head and Neck Cancer Cells by Inhibiting the Nrf2-ARE Antioxidant Pathway.
Kim EH; Baek S; Shin D; Lee J; Roh JL
Oxid Med Cell Longev; 2017; 2017():5498908. PubMed ID: 29456786
[TBL] [Abstract][Full Text] [Related]
42. Self-assembled nanoscale coordination polymers carrying siRNAs and cisplatin for effective treatment of resistant ovarian cancer.
He C; Liu D; Lin W
Biomaterials; 2015 Jan; 36():124-33. PubMed ID: 25315138
[TBL] [Abstract][Full Text] [Related]
43. Tumor pH-functionalized and charge-tunable nanoparticles for the nucleus/cytoplasm-directed delivery of oxaliplatin and miRNA in the treatment of head and neck cancer.
Lo YL; Lin HC; Tseng WH
Acta Biomater; 2022 Nov; 153():465-480. PubMed ID: 36115656
[TBL] [Abstract][Full Text] [Related]
44. Suppression of Aurora-A-FLJ10540 signaling axis prohibits the malignant state of head and neck cancer.
Chen CH; Chang AY; Li SH; Tsai HT; Shiu LY; Su LJ; Wang WL; Chiu TJ; Luo SD; Huang TL; Chien CY
Mol Cancer; 2015 Apr; 14():83. PubMed ID: 25889801
[TBL] [Abstract][Full Text] [Related]
45. Potential use of cetrimonium bromide as an apoptosis-promoting anticancer agent for head and neck cancer.
Ito E; Yip KW; Katz D; Fonseca SB; Hedley DW; Chow S; Xu GW; Wood TE; Bastianutto C; Schimmer AD; Kelley SO; Liu FF
Mol Pharmacol; 2009 Nov; 76(5):969-83. PubMed ID: 19654225
[TBL] [Abstract][Full Text] [Related]
46. Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug.
Xu X; Xie K; Zhang XQ; Pridgen EM; Park GY; Cui DS; Shi J; Wu J; Kantoff PW; Lippard SJ; Langer R; Walker GC; Farokhzad OC
Proc Natl Acad Sci U S A; 2013 Nov; 110(46):18638-43. PubMed ID: 24167294
[TBL] [Abstract][Full Text] [Related]
47. Knockdown EIF3C Suppresses Cell Proliferation and Increases Apoptosis in Pancreatic Cancer Cell.
Jiao H; Zeng L; Yang S; Zhang J; Lou W
Dose Response; 2020; 18(3):1559325820950061. PubMed ID: 32973416
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of Glutaredoxin 5 predisposes Cisplatin-resistant Head and Neck Cancer Cells to Ferroptosis.
Lee J; You JH; Shin D; Roh JL
Theranostics; 2020; 10(17):7775-7786. PubMed ID: 32685019
[No Abstract] [Full Text] [Related]
49. SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells.
Leibowitz MS; Srivastava RM; Andrade Filho PA; Egloff AM; Wang L; Seethala RR; Ferrone S; Ferris RL
Clin Cancer Res; 2013 Feb; 19(4):798-808. PubMed ID: 23363816
[TBL] [Abstract][Full Text] [Related]
50. Small interfering RNA (siRNA)-based therapeutic applications against viruses: principles, potential, and challenges.
Kang H; Ga YJ; Kim SH; Cho YH; Kim JW; Kim C; Yeh JY
J Biomed Sci; 2023 Oct; 30(1):88. PubMed ID: 37845731
[TBL] [Abstract][Full Text] [Related]
51. The p53-reactivating small-molecule RITA enhances cisplatin-induced cytotoxicity and apoptosis in head and neck cancer.
Roh JL; Ko JH; Moon SJ; Ryu CH; Choi JY; Koch WM
Cancer Lett; 2012 Dec; 325(1):35-41. PubMed ID: 22634494
[TBL] [Abstract][Full Text] [Related]
52. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.
Günther M; Lipka J; Malek A; Gutsch D; Kreyling W; Aigner A
Eur J Pharm Biopharm; 2011 Apr; 77(3):438-49. PubMed ID: 21093588
[TBL] [Abstract][Full Text] [Related]
53. PAK2-c-Myc-PKM2 axis plays an essential role in head and neck oncogenesis via regulating Warburg effect.
Gupta A; Ajith A; Singh S; Panday RK; Samaiya A; Shukla S
Cell Death Dis; 2018 Aug; 9(8):825. PubMed ID: 30068946
[TBL] [Abstract][Full Text] [Related]
54. Knockdown of EIF3C promotes human U-2OS cells apoptosis through increased CASP3/7 and Chk1/2 by upregulating SAPK/JNK.
Gao W; Hu Y; Zhang Z; Du G; Yin L; Yin Z
Onco Targets Ther; 2019; 12():1225-1235. PubMed ID: 30863090
[TBL] [Abstract][Full Text] [Related]
55. Advances in siRNA delivery approaches in cancer therapy: challenges and opportunities.
Isazadeh H; Oruji F; Shabani S; Behroozi J; Nasiri H; Isazadeh A; Akbari M
Mol Biol Rep; 2023 Nov; 50(11):9529-9543. PubMed ID: 37741808
[TBL] [Abstract][Full Text] [Related]
56. A novel EIF3C-related CD8
Li R; Wang Y; Wen X; Cheng B; Lv R; Chen R; Hu W; Wang Y; Liu J; Lin B; Zhang H; Zhang E; Tang X
J Cancer Res Clin Oncol; 2024 Feb; 150(2):103. PubMed ID: 38400862
[TBL] [Abstract][Full Text] [Related]
57. Gelsolin regulates cisplatin sensitivity in human head-and-neck cancer.
Wang PW; Abedini MR; Yang LX; Ding AA; Figeys D; Chang JY; Tsang BK; Shieh DB
Int J Cancer; 2014 Dec; 135(12):2760-9. PubMed ID: 24771612
[TBL] [Abstract][Full Text] [Related]
58. Chemosensitization of cancer cells by siRNA using targeted nanogel delivery.
Dickerson EB; Blackburn WH; Smith MH; Kapa LB; Lyon LA; McDonald JF
BMC Cancer; 2010 Jan; 10():10. PubMed ID: 20064265
[TBL] [Abstract][Full Text] [Related]
59. miR145 targets the SOX9/ADAM17 axis to inhibit tumor-initiating cells and IL-6-mediated paracrine effects in head and neck cancer.
Yu CC; Tsai LL; Wang ML; Yu CH; Lo WL; Chang YC; Chiou GY; Chou MY; Chiou SH
Cancer Res; 2013 Jun; 73(11):3425-40. PubMed ID: 23548270
[TBL] [Abstract][Full Text] [Related]
60. Current advancements in self-assembling nanocarriers-based siRNA delivery for cancer therapy.
Kandasamy G; Maity D
Colloids Surf B Biointerfaces; 2023 Jan; 221():113002. PubMed ID: 36370645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
